Novavax (NVAX) Expected to Release Earnings on Thursday

Novavax (NASDAQ:NVAX) will likely be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Novavax to post earnings of ($0.44) per share and revenue of $55.63 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.69. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The firm had revenue of $239.24 million during the quarter, compared to analysts’ expectations of $149.19 million. During the same quarter last year, the company posted $0.99 earnings per share. The company’s revenue for the quarter was down 42.4% compared to the same quarter last year. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Trading Down 5.1%

Shares of NASDAQ:NVAX opened at $7.51 on Wednesday. Novavax has a 52-week low of $5.01 and a 52-week high of $11.55. The company has a market capitalization of $1.22 billion, a P/E ratio of 3.29, a price-to-earnings-growth ratio of 0.12 and a beta of 2.74. The company has a 50-day simple moving average of $8.39 and a 200 day simple moving average of $7.56. The company has a debt-to-equity ratio of 5.93, a quick ratio of 2.34 and a current ratio of 2.36.

Analyst Ratings Changes

NVAX has been the subject of several recent analyst reports. HC Wainwright raised their target price on shares of Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. TD Cowen lowered their target price on shares of Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novavax in a report on Wednesday, October 8th. Cantor Fitzgerald initiated coverage on shares of Novavax in a report on Friday, October 24th. They set an “overweight” rating and a $18.00 target price on the stock. Finally, Bank of America reaffirmed an “underperform” rating and set a $7.00 target price (down from $9.00) on shares of Novavax in a report on Wednesday, August 20th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.71.

Institutional Investors Weigh In On Novavax

Several hedge funds and other institutional investors have recently made changes to their positions in NVAX. HRT Financial LP grew its holdings in shares of Novavax by 191.8% during the 2nd quarter. HRT Financial LP now owns 615,649 shares of the biopharmaceutical company’s stock valued at $3,878,000 after purchasing an additional 404,676 shares during the last quarter. Thrivent Financial for Lutherans bought a new stake in shares of Novavax during the second quarter worth $1,321,000. Nebula Research & Development LLC bought a new stake in shares of Novavax during the second quarter worth $923,000. Headlands Technologies LLC bought a new stake in shares of Novavax during the second quarter worth $903,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Novavax during the second quarter worth $823,000. 53.04% of the stock is owned by institutional investors.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.